

PROPOSITION 65 SAFE HARBOR LEVELS:

No Significant Risk Levels for
Carcinogens and Maximum
Allowable Dose Levels for
Chemicals Causing Reproductive
Toxicity

November 2010

Reproductive and Cancer Hazard
Assessment Branch
Office of Environmental Health Hazard
Assessment
California Environmental Protection
Agency



TABLE OF CONTENTS

Proposition 65 Safe Harbor Levels Development.....	1
A. No Significant Risk Levels (NSRLs) Adopted in Regulation for Carcinogens.....	2
B. Maximum Allowable Dose Levels (MADLs) Adopted in Regulation for Chemicals Causing Reproductive Toxicity.....	9
C. Priority List for the Development of NSRLs for Carcinogens.....	11
D. Priority List for the Development of MADLs for Chemicals Causing Reproductive Toxicity.....	17

Proposition 65 Safe Harbor Levels Development

The Office of Environmental Health Hazard Assessment (OEHHA) of the California Environmental Protection Agency is the lead agency for the implementation of Proposition 65*. In that role, OEHHA has developed Proposition 65 safe harbor levels – no significant risk levels (NSRLs) for carcinogens and maximum allowable dose levels (MADLs) for chemicals that cause reproductive toxicity. The NSRL is the daily intake level calculated to result in one excess case of cancer in an exposed population of 100,000, assuming lifetime exposure at the level in question. The MADL is the level at which a chemical listed for reproductive toxicity would have no observable effect assuming exposure at 1,000 times that level. NSRLs and MADLs assist interested parties in determining whether warnings are required for exposures to listed chemicals, and whether discharges to sources of drinking water are prohibited. NSRLs and MADLs are promulgated as regulations in Title 27, California Code of Regulations,[†] sections 25705 and 25805, respectively.

Safe harbor levels may be based on risk assessments conducted outside OEHHA, as provided for in Sections 25705(b), 25705(c), and 25805. In some cases, this can expedite safe harbor development. However, the process of review and consideration of existing risk assessments can be a lengthy one, and will depend on the complexity of the scientific information underlying the assessment, as well as on available resources.

This document provides the status of the development and adoption of safe harbor levels for all chemicals on the Proposition 65 list. Part A reports NSRLs adopted in regulation for carcinogens. Part B reports MADLs adopted in regulation for chemicals that cause reproductive toxicity. Parts C and D give priority levels for development of NSRLs and MADLs, respectively. Parts C and D also include safe harbor levels that have been proposed, but not adopted, in regulation.

OEHHA assigns priority levels based on the following factors: availability and quality of scientific data for dose-response assessments, potential for exposure, resources available to perform the assessment, needs expressed by interested parties, and input from the public and the Attorney General's office. Priority assignments change as assessments are completed or the basis for the priority changes. Interested parties are invited to recommend changes in priority levels. In general, OEHHA gives priority to chemicals that are newly added to the Proposition 65 list and aims to propose safe harbor levels for them within one year of their addition to the list.

This status report will be updated on a regular basis.

* The Safe Drinking Water and Toxic Enforcement Act of 1986, codified at Health and Safety Code Section 25249.5

[†] All further section references are to Title 27 of the California Code of Regulations unless otherwise indicated.

A. No Significant Risk Levels (NSRLs) Adopted in Regulation for Carcinogens

The table below lists NSRLs for Proposition 65 carcinogens in regulation (Sections 25705 and 25709), in units of micrograms per day ($\mu\text{g}/\text{day}$). These levels provide “safe harbor” for persons subject to the Act, and do not preclude the use of alternative levels that can be demonstrated by their users as being scientifically valid.

A three-tiered procedure for development of NSRLs is currently in place. NSRLs may be based on:

- a *de novo* dose response assessment conducted or reviewed by OEHHA (Section 25705(b)),
- an assessment conducted by another state or federal agency (Section 25705(c)), or
- an expedited process conducted by OEHHA (Section 25705(d)).

The last column of the table below indicates which of these processes was used to develop the NSRL for each chemical. NSRLs represent the daily intake level calculated to result in a cancer risk of one excess case of cancer in 100,000 individuals exposed over a lifetime.

NSRLs for chemicals in bold have been adopted since the last report. If a chemical is removed from the Proposition 65 list, the regulatory process to remove the safe harbor level from regulation will be initiated.

Carcinogen	Level ($\mu\text{g}/\text{day}$)	Section
A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole)	2	25705(d)
Acetaldehyde	90 (inhalation)	25705(c)
Acetamide	10	25705(d)
2-Acetylaminofluorene	0.2	25705(d)
Acrylamide	0.2	25705(c)
Acrylonitrile	0.7	25705(b)
Actinomycin D	0.00008	25705(d)
AF-2; [2-(2-furyl)-3(5-nitro-2-furyl)acrylamide]	3	25705(d)
Aldrin	0.04	25705(b)
2-Aminoanthraquinone	20	25705(d)
σ -Aminoazotoluene	0.2	25705(d)
4-Aminobiphenyl	0.03	25705(d)
3-Amino-9-ethylcarbazole hydrochloride	9	25705(d)
1-Amino-2-methylantraquinone	5	25705(d)
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole	0.04	25705(d)
Amitrole	0.7	25705(d)
Aniline	100	25705(c)
σ -Anisidine	5	25705(d)
σ -Anisidine hydrochloride	7	25705(d)
Aramite	20	25705(d)
Arsenic	0.06 (inhalation) 10 (except inhalation)	25705(b) 25709

Carcinogen	Level (µg/day)	Section
Asbestos NSRL for fibers \geq 5 micrometers (μm) long and 0.3 μm wide, with a length/width ratio \geq 3:1 as measured by phase contrast microscopy.	100 fibers/day (inhalation)	25705(b)
Auramine	0.8	25705(d)
Azaserine	0.06	25705(d)
Azathioprine	0.4	25705(d)
Azobenzene	6	25705(c)
Benz[a]anthracene	0.033 (oral)	25705(b)
Benzene	6.4 (oral)	25705(b)
	13 (inhalation)	25705(b)
Benzidine	0.001	25705(b)
Benzo[b]fluoranthene	0.096 (oral)	25705(b)
Benzo[j]fluoranthene	0.11 (oral)	25705(b)
Benzo[f]uran	1.1	25705(b)
Benzo[a]pyrene	0.06	25705(c)
Benzyl chloride	4	25705(c)
Benzyl violet 4B	30	25705(d)
Beryllium	0.1	25709
Beryllium oxide	0.1	25705(c)
Beryllium sulfate	0.0002	25705(c)
Bis(2-chloroethyl)ether	0.3	25705(b)
Bis(chloromethyl)ether	0.02	25705(b)
Bromodichloromethane	5	25705(c)
Bromoform	64	25705(b)
1,3-Butadiene	0.4	25705(c)
Butylated hydroxyanisole	4000	25705(b)
beta-Butyrolactone	0.7	25705(d)
Cadmium	0.05 (inhalation)	25705(b)
Captafol	5	25705(d)
Captan	300	25705(d)
Carbazole	4.1	25705(d)
Carbon tetrachloride	5	25705(b)
N-Carboxymethyl-N-nitrosourea	0.70	25705(b)
Chlorambucil	0.002	25705(d)
Chlordane	0.5	25705(c)
Chlordecone (Kepone)	0.04	25705(d)
Chlorendic acid	8	25705(d)
Chlorinated paraffins (Ave. chain length C12; approx. 60% chlorine by weight)	8	25705(d)
p-Chloroaniline	1.5	25705(b)
p-Chloroaniline hydrochloride	1.9	25705(b)
Chloroethane (Ethyl chloride)	150	25705(b)
Chloroform	20 (oral)	25705(c)
	40 (inhalation)	25705(c)
Chloromethyl methyl ether (technical grade)	0.3	25705(d)
3-Chloro-2-methylpropene	5	25705(d)
4-Chloro-ortho-phenylenediamine	40	25705(d)
Chlorothalonil	200	25705(d)
p-Chloro-ortho-toluidine	3	25705(d)

Carcinogen	Level (µg/day)	Section
<i>p</i> -Chloro- <i>o</i> -toluidine, hydrochloride	3.3	25705(d)
Chlorozotocin	0.003	25705(d)
Chromium (hexavalent)	0.001 (inhalation)	25705(b)
Chrysene	0.35 (oral)	25705(b)
C.I. Basic Red 9 monohydrochloride	3	25705(d)
C.I. Direct Blue 218	50	25705(b)
Cinnamyl anthranilate	200	25705(d)
Coke oven emissions	0.3	25705(c)
<i>p</i> -Cresidine	5	25705(d)
Cupferron	3	25705(d)
Cyclophosphamide (anhydrous)	1	25705(d)
Cyclophosphamide (hydrated)	1	25705(d)
D&C Red No. 9	100	25705(d)
Dacarbazine	0.01	25705(d)
Daminozide	40	25705(d)
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	9	25705(d)
DDT, DDE, DDD (in combination)	2	25705(b)
DDVP (Dichlorvos)	2	25705(c)
2,4-Diaminoanisole	30	25705(d)
2,4-Diaminoanisole sulfate	50	25705(d)
4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline)	5	25705(d)
2,4-Diaminotoluene	0.2	25705(d)
Dibenz[a,h]anthracene	0.2	25705(d)
7H-Dibenzo[c,g]carbazole	0.0030 (oral)	25705(b)
Dibenzo[a,h]pyrene	0.0054 (oral)	25705(b)
Dibenzo[a,i]pyrene	0.0050 (oral)	25705(b)
1,2-Dibromo-3-chloropropane	0.1	25705(b)
<i>p</i> -Dichlorobenzene	20	25705(b)
3,3'-Dichlorobenzidine	0.6	25705(b)
1,1-Dichloroethane	100	25705(d)
1,2-Dichloroethane (Ethylene dichloride)	10	25705(b)
Dichloromethane (Methylene chloride)	200 (inhalation)	25705(b)
	50	25705(c)
1,2-Dichloropropane	9.7	25705(b)
Dieldrin	0.04	25705(b)
Di(2-ethylhexyl)phthalate (DEHP)	310	25705(b)
Diethylstilbesterol	0.002	25705(d)
Diglycidyl resorcinol ether (DGRE)	0.4	25705(d)
Dihydrosafrole	20	25705(d)
3,3'-Dimethoxybenzidine (<i>o</i> -Dianisidine)	0.15	25705(b)
3,3'-Dimethoxybenzidine dihydrochloride	0.19	25705(b)
4-Dimethylaminoazobenzene	0.2	25705(d)
trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole	2	25705(d)
7,12-Dimethylbenz(a)anthracene	0.003	25705(d)
3,3'-Dimethylbenzidine (<i>o</i> -Tolidine)	0.044	25705(b)
3,3'-Dimethylbenzidine dihydrochloride	0.059	25705(b)
Dimethylcarbamoyl chloride	0.05	25705(d)
1,2-Dimethylhydrazine	0.001	25705(d)
Dimethylvinylchloride	20	25705(d)
2,4-Dinitrotoluene	2	25705(c)

Carcinogen	Level (µg/day)	Section
1,4-Dioxane	30	25705(b)
Direct Black 38 (technical grade)	0.09	25705(d)
Direct Blue 6 (technical grade)	0.09	25705(d)
Direct Brown 95 (technical grade)	0.1	25705(d)
Disperse Blue 1	200	25705(d)
Epichlorohydrin	9	25705(b)
Estradiol 17b	0.02	25705(d)
Ethylbenzene	41 (oral) 54 (inhalation)	25705(b)
Ethyl-4,4'-dichlorobenzilate (Chlorobenzilate)	7	25705(d)
Ethylene dibromide	0.2 (oral) 3 (inhalation)	25705(b) 25705(b)
Ethyleneimine	0.01	25705(d)
Ethylene oxide	2	25705(b)
Ethylene thiourea	20	25705(d)
Folpet	200	25705(c)
Formaldehyde (gas)	40	25705(c)
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole	0.3	25705(d)
Furmecyclox	20	25705(c)
Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole)	0.1	25705(d)
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]-imidazole)	0.5	25705(d)
Gyromitrin (Acetaldehyde methylformylhydrazone)	0.07	25705(d)
HC Blue 1	10	25705(d)
Heptachlor	0.2	25705(c)
Heptachlor epoxide	0.08	25705(c)
Hexachlorobenzene	0.4	25705(b)
Hexachlorocyclohexane		
alpha isomer	0.3	25705(c)
beta isomer	0.5	25705(c)
gamma isomer	0.6	25705(c)
technical grade	0.2	25705(b)
Hexachlorodibenzodioxin	0.0002	25705(b)
Hexachloroethane	20	25705(d)
Hydrazine	0.04	25705(c)
Hydrazine sulfate	0.2	25705(c)
Hydrazobenzene (1,2-Diphenylhydrazine)	0.8	25705(d)
IQ (2-Amino-3-methylimidazo[4,5-f]quinoline)	0.5	25705(d)
Isobutyl nitrite	7.4	25705(d)
Lasiocarpine	0.09	25705(d)
Lead	15 (oral)	25705(b)
Lead acetate	23 (oral)	25705(b)
Lead phosphate	58 (oral)	25705(b)
Lead subacetate	41 (oral)	25705(b)
Me-A-alpha-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole)	0.6	25705(d)
MeIQ (2-amino-3,4-dimethylimidazo-[4,5-f]quinoline)	0.46	25705(d)

Carcinogen	Level (µg/day)	Section
MelQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline)	0.41	25705(d)
Melphalan	0.005	25705(d)
2-Methylaziridine (Propyleneimine)	0.028	25705(b)
Methyl carbamate	160	25705(d)
3-Methylcholanthrene	0.03	25705(d)
5-Methylchrysene	0.0084 (oral)	25705(b)
4,4'-Methylene bis(2-chloroaniline)	0.5	25705(d)
4,4'-Methylene bis(N,N-dimethyl)benzeneamine	20	25705(c)
4,4'-Methylene bis(2-methylaniline)	0.8	25705(d)
4,4'-Methylenedianiline	0.4	25705(d)
4,4'-Methylenedianiline dihydrochloride	0.6	25705(d)
Methylhydrazine	0.058 (oral)	25705(b)
	0.090 (inhalation)	25705(b)
Methylhydrazine sulfate	0.18	25705(b)
Methyl methanesulfonate	7	25705(d)
2-Methyl-1-nitroanthraquinone (of uncertain purity)	0.2	25705(d)
N-Methyl-N'-nitro-N-nitrosoguanidine	0.08	25705(d)
Methylthiouracil	2	25705(d)
Michler's ketone	0.8	25705(d)
Mirex	0.04	25705(d)
Mitomycin C	0.00009	25705(d)
Monocrotaline	0.07	25705(d)
5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)-amino] -2-oxazolidinone	0.18	25705(b)
MX (3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone)	0.11	25705(b)
Nalidixic acid	28	25705(d)
Naphthalene	5.8	25705(b)
2-Naphthylamine	0.4	25705(d)
Nickel refinery dust	0.8	25705(c)
Nickel subsulfide	0.4	25705(c)
Nitrilotriacetic acid	100	25705(d)
Nitrilotriacetic acid, trisodium salt monohydrate	70	25705(d)
5-Nitroacenaphthene	6	25705(d)
Nitrofen (technical grade)	9	25705(d)
Nitrofurazone	0.5	25705(d)
1-[(5-Nitrofurfurylidene)-amino]-2-imidazolidinone	0.4	25705(d)
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide	0.5	25705(d)
Nitromethane	39	25705(b)
N-Nitrosodi-n-butylamine	0.06	25705(b)
N-Nitrosodiethanolamine	0.3	25705(c)
N-Nitrosodiethylamine	0.02	25705(b)
N-Nitrosodimethylamine	0.04	25705(b)
p-Nitrosodiphenylamine	30	25705(d)
N-Nitrosodiphenylamine	80	25705(b)
N-Nitrosodi-n-propylamine	0.1	25705(b)
N-Nitroso-N-ethylurea	0.03	25705(b)
4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone	0.014	25705(d)
N-Nitrosomethylethylamine	0.03	25705(c)
N-Nitroso-N-methylurea	0.006	25705(b)
N-Nitroso-N-methylurethane	0.006	25705(d)
N-Nitrosomorpholine	0.1	25705(d)

Carcinogen	Level (µg/day)	Section
N-Nitrosornicotine	0.5	25705(d)
N-Nitrosopiperidine	0.07	25705(d)
N-Nitrosopyrrolidine	0.3	25705(c)
Pentachlorophenol	40	25705(c)
Phenacetin	300	25705(d)
Phenazopyridine	4	25705(d)
Phenazopyridine hydrochloride	5	25705(d)
Phenesterin	0.005	25705(d)
Phenobarbital	2	25705(d)
Phenoxybenzamine	0.2	25705(d)
Phenoxybenzamine hydrochloride	0.3	25705(d)
o-Phenylenediamine	26	25705(d)
o-Phenylenediamine dihydrochloride	44	25705(d)
Phenyl glycidyl ether	5.0	25705(b)
Phenylhydrazine	1.0	25705(b)
Phenylhydrazine hydrochloride	1.4	25705(b)
o-Phenylphenate, sodium	200	25705(d)
Polybrominated biphenyls	0.02	25705(b)
Polychlorinated biphenyls	0.09	25705(c)
Polygeenan	1200	25705(b)
Ponceau MX	200	25705(d)
Ponceau 3R	40	25705(d)
Potassium bromate	1	25705(d)
Procarbazine	0.05	25705(d)
Procarbazine hydrochloride	0.06	25705(d)
1,3-Propane sultone	0.3	25705(d)
beta-Propiolactone	0.05	25705(d)
Propylthiouracil	0.7	25705(d)
Reserpine	0.06	25705(d)
Safrole	3	25705(d)
Sterigmatocystin	0.02	25705(d)
Streptozotocin	0.006	25705(d)
Styrene oxide	4	25705(d)
Sulfallate	4	25705(d)
2,3,7,8-Tetrachlorodibenzo- <i>p</i> -dioxin	0.000005	25705(b)
1,1,2,2-Tetrachloroethane	3	25705(d)
Tetrachloroethylene	14	25705(c)
Tetranitromethane	0.059	25705(b)
Thioacetamide	0.1	25705(d)
4,4'-Thiodianiline	0.05	25705(d)
Thiourea	10	25705(d)
Toluene diisocyanate	20	25705(d)
ortho-Toluidine	4	25705(d)
ortho-Toluidine hydrochloride	5	25705(d)
Toxaphene	0.6	25705(b)
Trichloroethylene	50 (oral)	25705(b)
	80 (inhalation)	25705(b)
2,4,6-Trichlorophenol	10	25705(b)

Carcinogen	Level (µg/day)	Section
Trimethyl phosphate	24	25705(d)
Tris(1-aziridiny)phosphine sulfide (Thiotepa)	0.06	25705(d)
Tris(2,3-dibromopropyl)phosphate	0.3	25705(d)
Trp-P-1 (Tryptophan-P-1)	0.03	25705(d)
Trp-P-2 (Tryptophan-P-2)	0.2	25705(d)
Urethane (Ethyl carbamate)	0.7	25705(b)
Vinyl chloride	3	25705(b)
Vinyl trichloride (1,1,2-Trichloroethane)	10	25705(d)
2,6-Xylidine	110	25705(b)

B. Maximum Allowable Dose Levels (MADLs) Adopted in Regulation for Chemicals Causing Reproductive Toxicity

The following table is a compilation of MADLs in regulation (Section 25805) for Proposition 65 chemicals that cause reproductive toxicity. These levels represent the no observable effect level (NOEL) for the chemical, divided by 1,000. NOELs are set in accordance with procedures specified in Section 25803. MADLs are reported in units of micrograms per day ($\mu\text{g}/\text{day}$).

Chemical Listed as Causing Reproductive Toxicity	Level ($\mu\text{g}/\text{day}$) ^a
Benzene	24 (oral) 49 (inhalation)
Cadmium	4.1 (oral)
2,4-DB (2,4-dichlorophenoxybutyric acid)	910
1,2-Dibromo-3-chloropropane (DBCP)	3.1 (oral) 4.3 (inhalation)
Di- <i>n</i> -butyl phthalate (DBP)	8.7
Di(2-ethylhexyl)phthalate (DEHP), for intravenous exposures only	4200 (adults) 600 (infant boys, age 29 days- 24 months) 210 (neonatal infant boys, age 0-28 days) [Levels for male children and adolescents can be calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803]
Di(2-ethylhexyl)phthalate (DEHP), for oral exposures only	410 (adults) 58 (infant boys, age 29 days-24 months) 20 (neonatal infant boys age 0-28 days) [Levels for male children and adolescents can be calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803]
Di- <i>n</i> -hexyl phthalate (DnHP)	2,200 (oral)
<i>m</i> -Dinitrobenzene	38
Disodium cyanodithiomidocarbonate	56 (oral) [170 (oral) for a 32% pesticidal formulation]
Ethyl dipropylthiocarbamate	700 (oral and inhalation) 6700 (dermal)
Ethylene glycol monoethyl ether (EGEE)	750 (oral) 960 (inhalation)
Ethylene glycol monoethyl ether acetate (EGEEA)	1100 (oral) 1400 (inhalation)

Chemical Listed as Causing Reproductive Toxicity	Level (µg/day) ^a
Ethylene glycol monomethyl ether	63 (oral)
Ethylene glycol monomethyl ether acetate	98 (oral)
Ethylene oxide	20
Hydramethylnon	120 (oral)
Lead	0.5
Linuron	460
Methyl bromide as a structural fumigant	810 (inhalation)
N-Methylpyrrolidone	3200 (inhalation) 17000(dermal)
Potassium dimethyldithiocarbamate	720
Quizalofop-ethyl	590
Sodium dimethyldithiocarbamate	23 (oral) [58 (oral) for a 40% pesticidal formulation]
Thiophanate-methyl	600 (oral)
Toluene	7000 ^b

^a Where a source or product results in exposures by multiple routes, the total exposure must be considered. For example, the MADL for benzene is exceeded when the absorbed dose exceeds 24 µg/day. If only inhalation and oral exposure occurs, the benzene MADL is exceeded when:

$$(\text{oral dose} \div 24 \text{ } \mu\text{g/day}) + (\text{inhalation dose} \div 49 \text{ } \mu\text{g/day}) > 1.0$$

^b Level represents absorbed dose (rounded from 6,525 µg/day). Since 100% of ingested toluene is absorbed, oral dose is equivalent to administered dose. It is assumed that roughly 50% of the dose administered by the inhalation route is absorbed. Therefore the MADL for inhaled toluene is 13,000 µg/day (rounded from 13,050 µg/day), corresponding to an absorbed dose of 6,525 µg/day.

C. Priority List for the Development of NSRLs for Proposition 65 Carcinogens

OEHHA has developed the following priority list, which classifies into four priorities carcinogens for which NSRLs have not been adopted. OEHHA assigns priority levels based on the availability and quality of scientific data for dose-response assessments, potential for exposure, resources available to perform the assessment, need expressed by interested parties and input from the public and Attorney General's office. OEHHA anticipates proposing NSRLs for many of the chemicals in the first priority group within the next year, OEHHA anticipates proposing NSRLs within the next two to five years for many of the chemicals in the second priority group. It is unlikely that NSRLs for third and fourth priority chemicals will be released within the next five years.

Priority assignments change as assessments are completed or the basis for the priority changes. Any interested party may submit recommendations to OEHHA for revising the priority assignment for any of the chemicals listed, preferably with supporting rationale for the change in priority. In general, OEHHA will give priority to chemicals that are newly added to the Proposition 65 list and propose safe harbor levels for them within one year of their addition to the list.

If a level is currently being proposed for adoption in regulation, it is given below. Chemicals in bold font have been added to the Proposition 65 list or changed in priority status since the last report.

First Priority for NSRL Development

Bromate
Bromochloroacetic acid
Bromoethane
Carbaryl
Cumene
Dibromoacetic acid
1,3-Dichloro-2-propanol
Diclofop-methyl
Furan
Glycidol (Proposed: 0.54 µg/day)
2,4-Hexadienal (89% trans, trans isomer;
11% cis, trans isomer)
N-Methylolacrylamide
3-Monochloropropane-1,2-diol
Ochratoxin A
Oryzalin
Propylene glycol mono-*t*-butyl ether
Pyridine
Resmethrin
1,2,3-Trichloropropane
2,4,6-Trinitrotoluene (Proposed: 8.2 µg/day)

Second Priority for NSRL Development

Alachlor
p-Aminoazobenzene
Aniline hydrochloride
Anthraquinone
Antimony oxide
Benzotrichloride
2,2-Bis(bromomethyl)-1,3-propanediol
Catechol
Ceramic fibers (airborne particles of respirable size)
1-Chloro-4-nitrobenzene
Chloroprene
5-Chloro-*o*-toluidine and its strong acid salts
C. I. Acid Red 114
C.I. Direct Blue 15
Cobalt sulfate heptahydrate
D&C Orange No. 17
Diaminotoluene (mixed)
Dichloroacetic acid
3,3'-Dichlorobenzidine dihydrochloride
1,4-Dichloro-2-butene
1,3-Dichloropropene
Diesel engine exhaust
Diethyl sulfate
Dimethyl sulfate
1,1-Dimethylhydrazine (UDMH)
Indium phosphide
Isoprene
Methyleugenol
Methyl iodide
1-Naphthylamine
Nitrapyrin
Nitrobenzene
2-Nitropropane
o-Nitrotoluene
o-Phenylphenol
Progesterone
Propoxur
Propylene oxide
Quinoline and its strong acid salts
Spirodiclofen
Tetrafluoroethylene
Tris(2-chloroethyl)phosphate
Vanadium pentoxide (orthorhombic crystalline form)
Vinyl bromide
4-Vinylcyclohexene

Third Priority for NSRL Development

Acetochlor
Acifluorfen sodium
Aflatoxins
1-Amino-2,4-dibromoanthraquinone

Areca nut
Azacitidine
Benthiavalicarb-isopropyl
Benzidine-based dyes
Benzo[k]fluoranthene
Betel quid without tobacco
N,N-Bis(2-chloroethyl)-2-naphthylamine
Bischloroethyl nitrosourea (BCNU) (Carmustine)
Bis(2-chloro-1-methylethyl)ether, technical grade
1,4-Butanediol dimethanesulfonate (Busulfan)
Cacodylic acid
Carbon black (airborne, unbound particles of respirable size)
Chloramphenicol
Chlordimeform
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
Chlorotrianisene
Ciclosporin (Cyclosporin A; Cyclosporine)
Cidofovir
C.I. Solvent Yellow 14
Cisplatin
Clofibrate
Cobalt metal powder
Cobalt [II] oxide
Cobalt sulfate
Daunomycin
N,N'-Diacetylbenzidine
Diazoaminobenzene
Dibenz[a,h]acridine
Dibenz[a,j]acridine
Dibenzo[a,e]pyrene
Dibenzo[a,l]pyrene
2,3-Dibromo-1-propanol
3,3'-Dichloro-4,4'-diaminodiphenyl ether
Dienestrol
Diepoxybutane
1,2-Diethylhydrazine
Diisopropyl sulfate
3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine
3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'-dimethylbenzidine
1,6-Dinitropyrene
1,8-Dinitropyrene
2,6-Dinitrotoluene
2,4-/2,6-Dinitrotoluene mixture
Diphenylhydantoin (Phenytoin)
Diphenylhydantoin (Phenytoin), sodium salt
Di-n-propyl isocinchomeronate (MGK Repellent 326)
Diuron
Doxorubicin hydrochloride (adriamycin)
Estragole
Estrogens, steroidal
Estrone
Estropipate
Ethinylestradiol

Ethoprop
Ethyl acrylate
Fenoxycarb
Fumonisin B₁
Furazolidone
Fusarin C
Gallium arsenide
Ganciclovir
Gasoline engine exhaust (condensates/extracts)
Gemfibrozil
Glasswool fibers (airborne particles of respirable size)
Glycidaldehyde
Griseofulvin
Hexamethylphosphoramide
1-Hydroxyanthraquinone
Indeno[1,2,3-cd]pyrene
Iprodione
Iprovalicarb
Isoxaflutole
Lactofen
Mancozeb
Maneb
Medroxyprogesterone acetate
Mepanipirim
Merphalan
Mestranol
Metham sodium
Methylmercury compounds
Metiram
Metronidazole
Mustard Gas
Nafenopin
Nickel and nickel compounds
Nickel carbonyl
Niridazole
o-Nitroanisole
4-Nitrobiphenyl
6-Nitrochrysene
2-Nitrofluorene
1-Nitropyrene
4-Nitropyrene
Nitrogen mustard (Mechlorethamine)
Nitrogen mustard hydrochloride (Mechlorethamine HC1)
N-Nitrosomethylvinylamine
N-Nitrososarcosine
Norethisterone (Norethindrone)
Oxadiazon
Oxazepam
Oxythioquinox (Chinomethionat)
Oxymetholone
Panfuran S
PhiP
Pirimicarb
Polychlorinated dibenzo-*p*-dioxins

Polychlorinated dibenzofurans
Primidone
Procymidone
Pronamide
Propachlor
Propargite
Radionuclides
Selenium sulfide
Silica, crystalline (airborne particles of respirable size)
Spironolactone
Stanozolol
Strong inorganic acid mists containing sulfuric acid
Sulfasalazine (salicylazosulfapyridine)
Tamoxifen and its salts
Terrazole
Testosterone and its esters
p-a,a,a-Tetrachlorotoluene
Thiodicarb
Thiouracil
Thorium dioxide
Tresulfan
Trichlormethine (Trimustine hydrochloride)
2,4,5-Trimethylaniline and its strong acid salts
Triphenyltin hydroxide
Trypan blue (commercial grade)
Uracil mustard
Vinclozolin
4-Vinyl-1-cyclohexene diepoxide
Vinyl fluoride
Wood dust
Zileuton

Fourth Priority for NSRL Development

Alcoholic beverages
2-Aminofluorene
4-Amino-2-nitrophenol
Amsacrine
Analgesic mixtures containing phenacetin
Aristolochic acid
Betel quid with tobacco
Bitumens, extracts of steam-refined
Bracken fern
Caffeic acid
Carbon-black extracts
Certain combined chemotherapy for lymphomas
Citrus Red No. 2
Conjugated estrogens
Creosotes
Cycasin
Cytembena
D&C Red No. 8
D&C Red No. 19
3,7-Dinitrofluoranthene

3,9-Dinitrofluoranthene
Erionite
Ethyl methanesulfonate
Herbal remedies containing plant species of the genus *Aristolochia*
Iron dextran complex
Lynestrenol

Marijuana Smoke

8-Methoxypsoralen with ultraviolet A therapy
5-Methoxypsoralen with ultraviolet A therapy
Methylazoxymethanol
Methylazoxymethanol acetate
Nitrogen mustard N-oxide
Nitrogen mustard N-oxide hydrochloride
3-(N-Nitrosomethylamino)propionitrile
Norethynodrel
Oil Orange SS
Oral contraceptives, combined
Oral contraceptives, sequential
Palygorskite fibers
Phenolphthalein
Residual (heavy) fuel oils
Riddelliine
Shale-oils
Soots, tars, and mineral oils
Talc containing asbestiform fibers
Tobacco, oral use of smokeless products
Tobacco smoke
Toxins derived from *Fusarium moniliforme* (*Fusarium verticillioides*)
Unleaded gasoline (wholly vaporized)
Zalcitabine
Zidovudine (AZT)

D. Priority List for the Development of MADLs for Chemicals Causing Reproductive Toxicity

OEHHA has developed the following priority list, which divides into three priorities chemicals causing reproductive toxicity for which MADLs have not been adopted. OEHHA assigns priority levels based on the availability and quality of scientific data for dose-response assessments, potential for exposure, resources available to perform the assessment, need expressed by interested parties, and input from the public and the Attorney General's office. OEHHA anticipates proposing MADLs for many of the chemicals in the first priority group within the next year, and for second priority chemicals within the next two to five years. It is unlikely that MADLs for chemicals in the third priority group will be released within the next five years.

Priority assignments change as assessments are completed or the basis for the priority changes. Any interested party may submit recommendations to OEHHA on revising the priority assignment for any of the chemicals listed, preferably with supporting rationale for the change in priority. In general, OEHHA will give priority to chemicals that are newly added to the Proposition 65 list and propose safe harbor levels for them within one year of their addition to the list.

If a level is currently being proposed for adoption in regulation, it is given below. Chemicals in bold font have been added to the Proposition 65 list or changed in priority status since the last report.

First Priority for MADL Development

Amitraz
1-Bromopropane
Bromoxynil octanoate
1,3-Butadiene
Butyl benzyl phthalate (BBP)
N-Butyl glycidyl ether
Carbaryl
Chloroform
2-Chloropropionic acid
Chlorsulfuron
Chromium (hexavalent compounds)
Cycloate
Dichloroacetic acid
Diglycidyl ether
Di-isodecyl phthalate (DIDP)
N, N-Dimethylacetamide
2-Ethylhexanoic acid
Ethyl-tert-butyl ether (EBTE)
Hexafluoroacetone
Metham sodium
Methyl n-butyl ketone
Methyl isocyanate
Myclobutanil
Nitrobenzene
Nitrous oxide

p,p'-Oxybis(benzenesulfonyl hydrazide)
Phenyl glycidyl ether
Phenylphosphine
Tert-amyl methyl ether (TAME)
1,3,5-Triglycidyl-s-triazinetrione
Vinclozolin
Vinyl cyclohexene dioxide
4-Vinylcyclohexene

Second Priority for MADL Development

Arsenic (inorganic oxides)
Bromacil lithium salt
Bromoxynil
2-Bromopropane
Carbon disulfide
Cocaine
Dichlorophene
Diclofop methyl
Ethylene thiourea
Fenoxaprop ethyl
Fluazifop butyl
Fluvalinate
Mercury and mercury compounds
Methazole
Methyl mercury
Metiram
Nabam
Nicotine
Nitrapyrin
Oxadiazon
Oxydemeton methyl
Oxythioquinox (Chinomethionat)
Propargite
Resmethrin
Sodium fluoroacetate
Terbacil
2,3,7,8-Tetrachlorodibenzo-para-dioxin (TCDD)
Triadimefon
Tributyltin methacrylate
Triforine
Triphenyl tin hydroxide

Third Priority for MADL Development

Acetazolamide
Acetohydroxamic acid
Actinomycin D
All-trans retinoic acid
Alprazolam
Altretamine
Amantadine hydrochloride
Amikacin sulfate
Aminoglutethimide
Aminoglycosides

Aminopterin
Amiodarone hydrochloride
Amoxapine
Anabolic steroids
Angiotensin converting enzyme (ACE) inhibitors
Anisindione
Aspirin
Atenolol
Auranofin
Azathioprine
Barbiturates
Beclomethasone dipropionate
Benomyl
Benzphetamine hydrochloride
Benzodiazepines
Bischloroethyl nitrosourea (BCNU) (Carmustine)
Butabarbital sodium
1,4-Butanediol dimethanesulfonate (Busulfan)
Carbamazepine
Carbon monoxide
Carboplatin
Chenodiol
Chlorambucil
Chlorcyclizine hydrochloride
Chlordecone (Kepone)
Chlordiazepoxide
Chlordiazepoxide hydrochloride
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)
Cidofovir
Cladribine
Clarithromycin
Clobetasol propionate
Clomiphene citrate
Clorazepate dipotassium
Codeine phosphate
Colchicine
Conjugated estrogens
Cyanazine
Cycloheximide
Cyclophosphamide (anhydrous)
Cyclophosphamide (hydrated)
Cyhexatin
Cytarabine
Dacarbazine
Danazol
Daunorubicin hydrochloride
o,p' -DDT
p,p' -DDT
Demeclocycline hydrochloride (internal use)
Diazepam
Diazoxide
Dichlophenamide
1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE)
Dicumarol

Diethylstilbestrol (DES)
Diflunisal
Dihydroergotamine mesylate
Diltiazem hydrochloride
o-Dinitrobenzene
p-Dinitrobenzene
2,4-Dinitrotoluene
2,6-Dinitrotoluene
Dinitrotoluene (technical grade)
Dinocap
Dinoseb
Diphenylhydantoin (Phenytoin)
Doxorubicin hydrochloride (adriamycin)
Doxycycline (internal use)
Doxycycline calcium (internal use)
Doxycycline hyclate (internal use)
Doxycycline monohydrate (internal use)
Endrin
Environmental tobacco smoke (ETS)
Epichlorohydrin
Ergotamine tartrate
Estropipate
Ethionamide
Ethyl alcohol in alcoholic beverages
Ethylene dibromide
Etodolac
Etoposide
Etretinate
Filgrastim
Flunisolide
Fluorouracil
Fluoxymesterone
Flurazepam hydrochloride
Flurbiprofen
Flutamide
Fluticasone propionate
Ganciclovir
Ganciclovir sodium
Gemfibrozil
Goserelin acetate
Halazepam
Halobetasol propionate
Haloperidol
Halothane
Heptachlor
Hexachlorobenzene
Hexamethylphosphoramide
Histrelin acetate
Hydroxyurea
Idarubicin hydrochloride
Ifosfamide
Iodine-131
Isotretinoin
Leuprolide acetate

Levodopa
Levonorgestrel implants
Lithium carbonate
Lithium citrate
Lorazepam
Lovastatin
Mebendazole
Medroxyprogesterone acetate
Megestrol acetate
Melphalan
Menotropins
Meprobamate
Mercaptopurine
Methacycline hydrochloride
Methimazole
Methotrexate
Methotrexate sodium
Methyl chloride
Methyltestosterone
Midazolam hydrochloride
Minocycline hydrochloride (internal use)
Misoprostol
Mitoxantrone hydrochloride
Molinate
Nafarelin acetate
Neomycin sulfate (internal use)
Netilmicin sulfate
Nickel carbonyl
Nifedipine
Nimodipine
Nitrofurantoin
Nitrogen mustard (Mechlorethamine)
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)
Norethisterone (Norethindrone)
Norethisterone acetate (Norethindrone acetate)
Norethisterone (Norethindrone)/Ethinyl estradiol
Norethisterone (Norethindrone)/Mestranol
Norgestrel
Oxazepam
Oxymetholone
Oxytetracycline (internal use)
Oxytetracycline hydrochloride (internal use)
Paclitaxel
Paramethadione
Penicillamine
Pentobarbital sodium
Pentostatin
Phenacetamide
Phenprocoumon
Pimozide
Pipobroman
Plicamycin
Polybrominated biphenyls
Polychlorinated biphenyls

Pravastatin sodium
Prednisolone sodium phosphate
Procarbazine hydrochloride
Propylthiouracil
Pyrimethamine
Quazepam
Retinol/retinyl esters, when in daily dosages in
excess of 10,000 IU, or 3,000 retinol equivalents.
Ribavirin
Rifampin
Secobarbital sodium
Sermorelin acetate
Streptomycin sulfate
Streptozocin (streptozotocin)
Sulfasalazine (salicylazosulfapyridine)
Sulindac
Tamoxifen citrate
Temazepam
Teniposide
Testosterone cypionate
Testosterone enanthate
Tetracycline (internal use)
Tetracyclines (internal use)
Tetracycline hydrochloride (internal use)
Thalidomide
Thioguanine
Tobacco smoke (primary)
Tobramycin sulfate
Triazolam
Trientine hydrochloride
Trilostane
Trimethadione
Trimetrexate glucuronate
Uracil mustard
Urethane
Urofollitropin
Valproate (Valproic acid)
Vinblastine sulfate
Vincristine sulfate
Warfarin
Zileuton